For the first time, we have combined network pharmacology with transcriptomic analysis and comprehensively validated the PPARγ–TP53 dual regulatory axis mechanism through both in vitro and in vivo experiments, thereby providing a foundation for understanding the mechanisms by which emodin acts in CRC treatment and offering a more robust theoretical basis for clinical applications. The gene discussed is TP53; the disease is colorectal carcinoma.